Lara Lipton
Overview
Explore the profile of Lara Lipton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
2799
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lefkovits Y, Lipton L
J Med Case Rep
. 2024 Mar;
18(1):179.
PMID: 38521935
Background: Botulinum toxin, produced by the Gram-positive anaerobe Clostridium botulinum, is composed of seven antigenic subtypes (A, B, C, D, E, F, and G). Currently, only Botulinum toxin type A,...
2.
Mendis S, Lipton L, To Y, Ananda S, Michael M, McLachlan S, et al.
Br J Cancer
. 2024 Mar;
130(9):1477-1484.
PMID: 38448752
Background: Pancreatic cancer incidence is increasing in younger populations. Differences between early onset pancreatic cancer (EOPC) and later onset pancreatic cancer (LOPC), and how these should inform management warrant exploration...
3.
Maharaj A, Lubel J, Lam E, Clark P, Duncan O, George J, et al.
Hepatol Commun
. 2022 Sep;
6(11):3260-3271.
PMID: 36153817
Although there are several established international guidelines on the management of hepatocellular carcinoma (HCC), there is limited information detailing specific indicators of good quality care. The aim of this study...
4.
Santucci J, Tacey M, Thomson B, Michael M, Wong R, Shapiro J, et al.
Eur J Cancer
. 2022 Aug;
174:102-112.
PMID: 35988408
Background: First-line palliative chemotherapy regimens in advanced pancreatic ductal adenocarcinoma (PDAC) have not been compared in head-to-head phase III randomised controlled trials (RCT). Data on optimum first-line treatment and subsequent...
5.
Walpole I, Lee B, Shapiro J, Thomson B, Lipton L, Ananda S, et al.
Asia Pac J Clin Oncol
. 2022 Jul;
19(1):214-225.
PMID: 35831999
Background: Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resectable METHOD: A retrospective analysis of consecutive patients with localized PDAC between January 2016 and...
6.
Kim S, Kissane D, Richardson G, Senior J, Morgan J, Gregory P, et al.
Psychooncology
. 2021 Aug;
31(2):167-175.
PMID: 34460129
Objective: Identifying modifiable factors affecting work ability among cancer survivors is important. The primary aim of the present study was to examine the effects of depression and related psychological factors...
7.
Fujihara K, Corrales Benitez M, Cabalag C, Zhang B, Ko H, Liu D, et al.
Mol Cancer Ther
. 2021 Jul;
20(10):1858-1867.
PMID: 34315763
APR-246 (eprenetapopt) is in clinical development with a focus on hematologic malignancies and is promoted as a mutant-p53 reactivation therapy. Currently, the detection of at least one mutation is an...
8.
Choi C, Choi J, Houli N, Smith M, Usatoff V, Lipton L, et al.
ANZ J Surg
. 2021 Apr;
91(5):915-920.
PMID: 33870626
Background: Pancreatic ductal adenocarcinoma (PDAC) presents as unresectable disease in 80% of patients. Limited Australian data exists regarding management and outcome of palliative management for PDAC. This study aims to:...
9.
Phan T, Patwala K, Lipton L, Knight V, Aga A, Pianko S
Curr Oncol
. 2021 Feb;
28(1):898-902.
PMID: 33617506
Immune checkpoint inhibitors (ICIs) have led to major therapeutic advances in the management of malignancy. Despite promising outcomes for some cancers, ICIs are linked to unique side-effects known as immune-related...
10.
Body A, Wong R, Shapiro J, Jalali A, McLachlan S, Ananda S, et al.
Intern Med J
. 2020 Oct;
52(1):49-56.
PMID: 33040452
Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is highly lethal. Combination chemotherapy regimens improve overall survival (OS). Historically, only one-third of mPDAC patients in Victoria received chemotherapy. Aim: To describe current...